Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | PRKACG | P22612 | 1/20 | 0.36 |
| ▸ | PRKACB | P22694 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447301 | 1.00 | PRKACA (0.36) | PRKACAPRKACGPRKACBL3MBTL1MAPK1 | |
| SCHEMBL27810450 | 0.78 | BCL6 (0.37) | L3MBTL1MAPK1NTRK1PIM1ACVR1 | |
| SCHEMBL31437529 | 0.78 | KCNMA1 (0.36) | L3MBTL1NTRK1PIM1ACVR1TDP1 | |
| SCHEMBL19139422 | 0.78 | NTRK1 (0.42) | NTRK1PIM1ACVR1TDP1ALDH1A1 | |
| SCHEMBL565899 | 0.78 | HTT (0.41) | PRKACAPRKACGPRKACBNTRK1PIM1 | |
| SCHEMBL3828718 | 0.78 | ALDH1A1 (0.44) | NTRK1PIM1ACVR1ALDH1A1MEN1 | |
| SCHEMBL4657787 | 0.78 | KCNMA1 (0.36) | PRKACAPRKACGPRKACBL3MBTL1MAPK1 | |
| SCHEMBL2937411 | 0.78 | LRRK2 (0.40) | L3MBTL1MAPK1NTRK1PIM1ACVR1 | |
| SCHEMBL22531427 | 0.78 | PRKACA (0.47) | PRKACAPRKACGPRKACBL3MBTL1MAPK1 | |
| SCHEMBL28312764 | 0.78 | KDM4E (0.36) | PRKACAPRKACGPRKACBL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558498-A1 | NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-119546608-A | Novel imidazopyridine and pyrazolopyridine sulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-112566905-B | Substituted phenylpropenyl pyridine derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| EP-4374858-A2 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-3630291-B9 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024017857-A1 | NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| EP-3630291-B1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | disclosed |
| CN-109415358-B | 6-aminopyridin-3-ylthiazoles as ROR gamma t modulators | 詹森药业有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3967687-A1 | SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd (CN) | 2022-03-16 | — | — | EP | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2010130423-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130423-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130424-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130424-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2220083-A2 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010060589-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2009062676-A2 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRIA2 | PRKACA 3037/4885PRKACG 2547/4885PRKACB 2961/4885 |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | EIF2AK4, GCN1, GNAI2 | PRKACA 851/4885PRKACG 1226/4885PRKACB 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.